Pharmapian

Pharmapian is a South Korean biotechnology company specializing in the development of long-acting protein and peptide therapeutics. The company utilizes its proprietary Triple-MAP (Multi-functional Albumin-binding Protein) platform to significantly extend the half-life of biologics, reducing dosing frequency and improving patient compliance. Pharmapian's primary focus is on metabolic diseases, including obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH), with a pipeline featuring multi-agonists targeting GLP-1, GIP, and glucagon receptors. Additionally, the company is exploring applications in rare diseases and growth hormone deficiencies. By leveraging its albumin-binding technology, Pharmapian aims to provide more effective and convenient treatment options compared to existing short-acting therapies.